Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment
- 18 March 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 15 (4) , 299-311
Abstract
Introduction. DNA damaging drugs are widely used for the chemotherapeutic treatment of high-grade osteosarcoma (HGOS). In HGOS patients, several germline polymorphisms have been reported to impact on the development of adverse toxic events related to DNA damaging drugs treatment. Some of these polymorphisms, when present in tumor cells, may also influence treatment response and prognosis of HGOS patients. Area covered. In this review, the authors have focused on pharmacogenetic markers (mainly germline polymorphisms) described in patients with HGOS, which have proved or indicated to be related to the susceptibility to adverse toxic reactions and/or to influence response to DNA damaging drugs. The concordant and discordant results reported in different studies have also been discussed. Expert Opinion. Response and toxicity predisposition to DNA damaging drugs are influenced by genes encoding proteins involved in their uptake, efflux, activation, inactivation, and in DNA repair, activity of which may vary according to specific gene variations. In HGOS, there is a substantial medical need for biomarkers predictive for individual response and toxicity predisposition to DNA-targeting drugs, which may be used to tailor therapy in order to decrease the occurrence of adverse side effects and increase treatment efficacy and safety.Keywords
Funding Information
- Istituto Ortopedico Rizzoli (5 x mille contributions to the Rizzoli Institute)
- Italian Association for Cancer Research (IG 2018 - ID. 21487)
- Italian Ministery of Health (RF-2016-02361373)
This publication has 64 references indexed in Scilit:
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?European Journal of Cancer, 2011
- Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic StudyPLOS ONE, 2011
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcomaCancer, 2011
- The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivityMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011
- Drug transporters of platinum-based anticancer agents and their clinical significanceDrug Resistance Updates, 2011
- Glutathione S-transferase polymorphisms in osteosarcoma patientsPharmacogenetics and Genomics, 2010
- Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patientsThe Pharmacogenomics Journal, 2009
- Late Relapse in OsteosarcomaJournal of Pediatric Hematology/Oncology, 2006
- The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancerCancer Treatment Reviews, 2005